INTRODUCTION
Carnitine deficiency related to epilepsy or antagonism of carnitine by antiepileptic drugs (AEDs) has attracted increasing attention since the first recognition of a neuromuscular deficiency syndrome in 1973'. Carnitine deficiency is linked to the potentially fatal hepatotoxicity that occasionally attends valproate therapy, particularly in children2, and has been documented in adult and pediatric patients taking valproate and other anticonvulsants3-9. The role of such deficiency in the lethargy, sedation, and cognitive disturbance that often attends chronic AED treatment is not clear". We measured serum total and free carnitine levels in an ambulatory population of epilepsy patients well-controlled on valproate monotherapy or valproate plus a second medication, and without apparent hepatic or neuromuscular adverse effects from drug treatment.
SUBJECTS AND METHODS
Serum total and free carnitine was determined on 77 occasions in 50 patients with partial and secondarily generalized or generalized seizures followed at the Ohio State University Epilepsy Center. Thirty patients were taking valproate monotherapy, while 45 were on polypharmacy with valproate plus carbamazepine (30), ethosuximide (lo), or phenytoin (5). All patients had therapeutic levels of valproate, carbamazepine, ethosuximide, or phenytoin, and blood chem- istries generally and live function tests particularly were within the normal range, as were serum creatine kinase levels. In addition to the over-thecounter medications, other medications taken at the time included tricyclic antidepressants for sleep disturbance or mood lability (6 patients), anti-inflammatory or vasoconstrictive medica; tions for vascular or tension headaches (5 patients), antihistamines (4 patients), and oral contraceptives (29 patients).
Thirty patients had partial seizures with secondary generalization or primarily generalized seizures, indicated by EEG-recorded seizures or bilaterally-synchronous epileptiform activity on interictal EEG, while 20 patients had partial seizures and focal slowing or epileptiform discharges on EEG. Thirty-four patients were female and 16 male, and ages ranged from 16 to 50 years. Thirty-five patients had interictal behavioural symptoms involving ponderousness, stickiness, loquacity, and hypergraphia, although they had not previously received psychiatric diagnoses; 10 of these had consulted the counseling services or support groups of the Epilepsy Association of Central Ohio due to emotional, situational, or family difficulties. Forty patients reported weakness, myalgia, fatigue, sleep disturbances, or weakness. All patients had normal neurologic examinations, and cerebral structural lesions had been excluded during the previous evaluation of their epilepsy. No patients had known metabolic or nutritional disorders, none had dietary deficiencies or peculiarities, and none had known acute or chronic medical illnesses.
Serum levels of total and free camitine were determined by a 14 C-Radioisotope enzymatic technique (Mayo Medical Laboratories, Rochester, MN, USA Carnitine levels in patients and controls, partial and generalized seizure patients, patients with and without interictal behavioural symptoms, and individuals with myalgic symptoms and those without were compared by r-test. Chi-square was utilized to compare the incidence of abnormal carnitine levels in.age, gender, and seizure classification groups.
RESULTS
Serum carnitine levels are summarized in Table 1 . Thirty-five per cent of patients had abnormally low free carnitine levels and 38.8% had abnormally low total camitine levels. Twenty-eight per cent of females and 41.7% of females had reduced free camitine, whilst 40% of females and 37.5% of males had reduced total carnitine. The differences in hypocamitinemia were not significant when compared .by decade of age, gender or seizure type. Mean free and total carnitine levels were significantly lower among the seizure patients than among controls, however (P < O.Ol), and generalized seizure patients had lower carnitine levels than those with partial seizures (P < 0.05). Patients taking valproate plus other medications had significantly lower carnitine levels (P ~0.01) but there was no correlation between carnitine and valproate levels. Patients with interictal disturbance of personality and behaviour had lower camitine levels than those not affected, but the difference was not significant, and the incidence of abnormally low carnitine levels was not significantly increased. Patients with fatigue, lassitude, myalgia, and similar complaints had lower carnitine levels than those without symptoms (P CO.05) and the incidence of abnormal carnitine levels was increased in this group (P < 0.01). No differences between total and free carnitine levels were noted in these groups.
DISCUSSION
These findings suggest that carnitine levels may be abnormally low in ambulatory adult epileptic patients taking valproate monotherapy or twodrug regimens including valproate with no evidence of hepatic dysfunction or myopathy. No significant differences were found with age of between sexes, nor was a clear difference evident between seizure types. Polypharmacy appeared to increase the likelihood of low camitine levels, and this was also more likely with fatigue and myalgia. Interictal personality and behaviour disturbance was associated to a lesser extent with low carnitine levels.
Ohtani et af3 reported significant reduction in free and total camitine in 14 patients on valproate aged 3-21 years, although none of the patients were felt to be symptomatic.
Most of these patients were taking polypharmacy or medications in addition to valproate. Murphy and colleagues4 studied 13 children and found reduced total carnitine levels, with abnormally low levels in 22% without specific symptoms. Laub and coworkers' failed to find hypocarnitinemia in 14 patients aged 3-21 taking valproate alone, and in fact found an increase in acylcarnitine levels, while seven patients taking valproate plus other drugs had a greater but not statistically significant decrease in carnitine levels. Melegh ef al6 showed significant reductions in free and total carnitine in 11 children, some of whom had neurologic deficit and mental handicap.
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Segade and colleagues', and 76% of those taking valproate and 22% of those on other medications had low camitine levels, with significant reduction in mean levels overall. Many of these patients were apparently unaffected by hypocarnitenemia, although specific symptoms or lack thereof were not indicated. Beghi ef al.' found carnitine deficiency in only 4% of patients taking valproate, and found few adverse effects of deficiency and no correlation between carnitine levels and symptoms. A significant decrease in carnitine levels, apparently without symptoms, was found with polypharmacy including valproate, Coulter" found a marked and symptomatic reduction in carnitine levels in six children with cerebral palsy and other handicaps, who had multiple problems and were taking multiple medications. It has been suggested that carnitine deficiency may be more significant and more often symptomatic in patients with underlying illnesses or neurological deficit complicating epilepsy than in those with seizures treated with valproate alone". A substantial number of our patients had lassitude, fatigue, and complaints of weakness and pain, which had nb obvious concomitants on examination and were unassociated with elevations of creatine kinase. None of these patients had past histories of neuromuscular disorder, and none developed further symptoms or signs in follow-up; consequently, they did not have further neuromuscular evaluation. This would be appropriate in subsequent studies, however, inasmuch as the development of muscle carnitine deficiency with valproate treatment has been reported". The significance of such an effect of valproate therapy for adult outpatients is uncertain, as the spectrum of valproate-related adverse effects, hepatotoxic and otherwise, is different in the pediatric and adult patient populations'*. Symptomatic carnitine deficiency may be relevant to the increasingly-recognized encephalopathy which may attend valproate therapy without hepatic failure or hyperammonemia'3, and it might be seen in valproate treatment of seizures attending certain metabolic disorders such as the melas syndrome, because of the occurrence of lactic acidosis with carnitine depletion14.
